Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Status:
Completed
Trial end date:
2018-06-08
Target enrollment:
Participant gender:
Summary
This study is being done to see if using the study drug, pembrolizumab, can shrink down
melanoma tumors enough so that they will be small enough to cut out, so that there will be no
cancer left in the body.
Eligible participants include those who have not received any systemic melanoma therapies
(i.e. participants do not have to fail ipilimumab or BRAF inhibitor) and those who have
failed all available systemic options (if the participant meets other inclusion / exclusion
criteria).